Pompe News | Pompe Support Network
Amicus releases phase 3 results in Pompe disease trial
Home - AMDA Pompe
New Pompe disease treatment 'exciting,' Amicus chairman says
Pompe Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union - Canadian Association of Pompe
Amicus' Opfolda wins positive CHMP opinion in Pompe Disease - Pharmaceutical Technology
Amicus's Pompe disease setback doesn't dent gene therapy enthusiasm | Evaluate
Amicus gears up to launch Pompe disease combination therapy in the UK - Pharmaceutical Technology
Amicus misses goal in Pompe phase 3 but still pushes for approval, showdown with Sanofi | Fierce Biotech
Convegno AIG 2021 - L'impegno di Amicus Therapeutics nella malattia di Pompe - YouTube
Amicus Puts Positive Spin on Failure of its Phase III Trial for Pompe Disease | BioSpace
Amicus Therapeutics (FOLD) Presents On Positive Pompe Phase 1/2 Data at World Muscle Society - Slideshow (NASDAQ:FOLD) | Seeking Alpha
Amicus drug for Pompe disease falls short in key clinical trial
Amicus Therapeutics secures $430M deal with Blackstone for Pompe disease combination treatment. | Pharmtales | Pharma News & Analysis posted on the topic | LinkedIn
Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease
Amicus therapy shows durable muscle function improvements in Pompe disease patients - STAT
UK approval for Pompe Disease therapy
Amicus Therapeutics Declares FDA Sanction and Introduction of Novel Therapy for Pompe Disease
Amicus fail dents Pompe pipeline | Evaluate
Convegno AIG 2021 - L'impegno di Amicus Therapeutics nella malattia di Pompe - YouTube
European Commission approves Amicus Therapeutics' Pompe disease therapy - PMLiVE
